can be found in Müller cells, indicating the involvement of NGF signaling in the physiologic and pathological processes of Müller cells. In addition to a neuroprotective role, NGF exerts a proangiogenic role in various pathological conditions, such as ischemia-induced retinal neovascularization and a hindlimb ischemic model, by activating the TrkA and VEGFR-2 pathways in endothelial cells [18, 19] . In cultured human umbilical vein endothelial cells (HUVECs), NGF activates TrkA, triggering a mitogenic response and exerting an autocrine role in HUVECs [20] . Our previous study also demonstrated that NGF promoted angiogenesis via the TrkA receptor in the ischemic retina, and Müller cell activation is required in inflammation-induced retinal neovascularization [21] . However, little is known about the potential of NGF to induce VEGF generation in Müller cells.
Müller cells are active players in nearly all forms of retinal injury and disease [22, 23] . They undergo reactive gliosis, presented by the proliferation of Müller cells and the expression of glial fibrillary acidic protein (GFAP) in response to neuronal damage and other insults in an attempt to protect the tissue from further damage [24] [25] [26] . However, lasting gliosis releases many inflammatory cytokines, resulting in secondary injury and accelerating disease progress. For example, Müller cell proliferation is required in the occurrence and development of proliferative vitreoretinopathy and may be regarded as a limiting factor in the recovery of vision after reattachment [27] . Previous studies reported that many growth factors, such as bFGF and endothelin-2, induce the hypertrophy and proliferation of Müller cells in detached retinas [28] [29] [30] . However, the role of the classic neuroprotective factor NGF in the proliferation of Müller cells is still unknown and must be investigated.
In this study, we investigated the effect of NGF on VEGF generation in Müller cells and their proliferation and explored the underlying signaling pathway. We provide direct evidence that NGF promotes the generation and secretion of VEGF in Müller cells via extracellular signal-regulated kinases 1/2 (ERK1/2) and phosphatidylinositol 3-kinase (PI3K)/AKT signaling. In addition, NGF enhances the proliferation of Müller cells in a time-dependent manner. The results will help us better understand the role of NGF in VEGF production derived from Müller cells and the molecular mechanisms of Müller cell proliferation, which is involved in many retinal angiogenic and proliferative diseases.
METHODS
Primary Müller cell culture: C57BL/6J pups were sacrificed at postnatal 4-7 days, and their eyes were removed. Then, the retinas were isolated with care to avoid contamination from the RPE and the ciliary epithelium. They were chopped into approximately 1 mm 2 pieces and cultured in DMEM/F12 (1:1 ratio of Dulbecco's modified Eagle's medium and Ham's F12 medium; Life Technologies, Grand Island, NY) with 10% fetal bovine serum (FBS; Life Technologies, Grand Island, NY) in a humidified environment of 5% (vol./vol.) CO 2 at 37 °C for 3-4 days. Half of the floating retinal aggregates and debris was removed, and the dish was replenished with complete medium. After 3 days, the retinal aggregates were washed by vigorous rinsing, and the cells were kept in and fed with 90% DMEM/F12 (Life Technologies) plus 10% FBS, leaving a purified flat cell population of Müller cells attached to the bottom of the dish. After the second passage, the cultured cells were validated as being Müller cells with positive immunocytochemical staining using antibody against glutamine synthetase (GS), which is specifically localized in retinal Müller cells. Non-serum DMEM/F12 medium was added to the dishes, and the culture was incubated overnight before further analysis.
Cell treatment:
The cells were stimulated with recombinant NGF after serum starvation overnight (PeproTech, Rocky Hill, NJ). According to the manufacturer's recommendation, the NGF was reconstituted and stored in a buffer containing 0.1% bovine serum albumin (BSA) at a concentration of 1 mg/ ml. The working solution concentration of NGF was 100 ng/ ml, which contained 100 ng/ml of BSA. Thus, the control cells were treated with 100 ng/ml of BSA. Serum-free DMEM/F12 medium was used when the Müller cells were treated with NGF and the inhibitors. For the inhibitor treatments, the cells were pretreated with the inhibitors, including 10 nM and 20 nM K252a (tyrosine inhibitor of TrkA receptor; Calbiochem, San Diego, CA), 10 μM and 20 μM U0126 (ERK1/2 pathway inhibitor; CST), or 10 μM and 20 μM LY294002 (PI3K/AKT inhibitor; Calbiochem) for 30 min and were then stimulated with NGF. The concentration of these inhibitors was chosen according to previous reports, which showed that 10 μM and 20 μM U0126 or LY294002 were widely used in Müller and astrocyte glia cell experiments without toxic effects. After 5, 15, or 30 min treatment, the cell lysate was used for western blot. After 12 and 24 h, the supernatants were collected for ELISA, and after 24, 48, and 72 h, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was performed in the cells as described [31, 32] .
GS-Müller cell identification and TrkA receptor expression by immunofluorescence staining:
The Müller cells were washed with PBS (1X; 135 mM NaCl, 4.7 mM KCl, 10 mM Na 2 HPO 4 , 2 mM NaH 2 PO 4 , pH 7.4) twice and fixed for 20 min in 4% paraformaldehyde at room temperature. Then, the cells were blocked with 3% BSA in PBS for 1 h and incubated with 1:100 mouse monoclonal anti-GS antibody (Abcam, Cambridge, UK) and 1:100 rabbit anti-TrkA (Cell Signaling Technology, Beverly, MA) antibody overnight at 4 °C. After washing with PBS/0.1% Tween-20 three times, the cells were incubated with 1:200 Alexa 555-conjugated donkey ant-mouse/Alexa 488-conjugated donkey anti-rabbit antibodies (Cell Signaling Technology) at room temperature for 1 h. The nuclei were stained with 1:1,000 4',6-diamidino-2-phenylindole (DAPI) for 5 min, and the cells were analyzed under a confocal microscope (LSM 510 META; Carl Zeiss, Oberkochen, Germany). Fluorescence pictures were taken with identical exposure settings. For the negative control, the cells were stained without primary antibodies and showed no signals.
AKT and ERK1/2 phosphorylation by western blotting:
Cellular protein was harvested at the indicated time points and homogenized in lysis buffer (RIPA; Biocolors, Shanghai, China) containing a protease (Roche, Indianapolis, IN) and the phosphatase inhibitor phosSTOP (Roche). The protein concentration was determined with bicinchoninic acid (BCA) protein assay. Equal amounts of protein were run on a 10% (w/v) reducing sodium dodecyl sulfate (SDS) polyacrylamide electrophoresis gel. The gel was transferred to polyvinylidene fluoride (PVDF) membrane (Millipore Corporation, Billerica, MA) and blocked in 5% (w/v) BSA (MP Biomedicals, Santa Ana, CA) in TBST (1X; 20 mM Tris-HCl, 150 mM NaCl and 0.1% Tween-20, pH 7.5) for 60 min. The membrane was incubated with primary antibody at 4 °C overnight. The primary antibodies included mouse anti-β-actin antibody (1:2,000 dilution; Abcam, Cambridge, UK), rabbit anti-ERK1/2 antibody (1:1,000 dilution; CST), rabbit anti-p-ERK1/2 antibody (1:1,000 dilution; CST), rabbit anti-AKT antibody (1:1,000 dilution; CST) and rabbit anti-p-AKT antibody (1:1,000 dilution; CST). Then, the membranes were washed with TBST three times. Next, the membranes were incubated with a horseradish peroxidase-conjugated secondary antibody at a concentration of 1:5,000 for 1 h at room temperature. The signals were developed with Super Signal West Dura extended duration substrate (Thermo Scientific, Rockford, IL), and the images were captured by an image station. The phosphorylated protein signal was normalized to the corresponding total protein signal after it was quantified using ImageJ software (National Institutes of Health). β-actin was also used as a loading control.
VEGF detection with ELISA and Müller cell proliferation with MTT assay:
The Müller cells seeded on 24-well or 96-well plates (Corning Inc., Corning, NY) were cultured in serum-free DMEM/F12 overnight and then treated with 100 ng/ml BSA, 100 ng/ml of recombinant NGF with or without K252a, U0126, and LY294002 for 12, 24, 48, and 72 h. At the appropriate time points, the supernatants of the treated Müller cells were collected, and VEGF levels were detected with a mouse VEGF ELISA kit (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions. In addition, an MTT assay (MP Biomedicals) was performed to detect cell viability using a microplate reader set to 570 nm, and the wavelength correction was set to 630 nm as described.
Statistical analysis: There were six samples in each group for the MTT assay and ELISA. A one-way analysis of variance (ANOVA) was used to compare the expression of VEGF and cell survival between the different treatment groups. Differences in VEGF secretion according to the ELISA between NGF treatment and the BSA control were analyzed with the Student t test. The statistical analyses were performed with the statistical software SPSS 13.0 (SPSS Inc., Chicago, IL). A p value of less than 0.05 was accepted as statistically significant. The data are reported as the mean ± standard error of the mean (SEM).
RESULTS

Expression of TrkA in murine Müller cells:
To demonstrate whether Müller cells express TrkA, we first isolated and cultured primary Müller cells from C57BL/6J mice and identified the cells by using antibodies against vimentin and GS, a specific marker of the Müller cells in the retina [33] [34] [35] . The immunostaining results revealed that most of the primary cells were GS-and vimentin-positive Müller cells (Appendix 1). TrkA, the high affinity receptor for NGF, was abundantly expressed in these primary Müller cells (Figure 1 ).
NGF improved VEGF expression in Müller cells:
Müller cell-derived VEGF is a significant contributor to retinal neovascularization as reported. To verify whether VEGF secretion by the Müller cells was affected by NGF treatment, we treated cells with 100 ng/ml of NGF for 12 or 24 h before the supernatants were collected for ELISA. Compared to the BSA control, an increase of 12.12% and 78.64% of secreted VEGF was observed in the Müller cells in the 12 and 24 h NGF treatment groups, respectively. In addition, the VEGF increase after 24 h was significantly higher than the increase after 12 h, whereas there was no statistical significance between the 12 and 24 h samples in the BSA treatment group (Figure 2 ; n=6, *p<0.05, ***p<0.001).
NGF activates the ERK1/2 and AKT pathway after TrkA recognition: The ERK1/2 and PI3K/AKT pathways are activated after extracellular growth factors bind to their respective transmembrane receptor tyrosine kinases [36] [37] [38] . To evaluate the involvement of ERK1/2 and AKT signaling in NGF-induced VEGF generation, we used western blotting to test the phosphorylation levels after NGF treatment for 5, 15, or 30 min. The results showed that NGF treatment promoted the phosphorylation of ERK1/2 in a time-dependent manner with maximum phosphorylation occurring at 5 min. Similarly, AKT phosphorylation increased in a time-dependent manner compared with the BSA-treated controls ( Figure 3A) . In addition, K252a, a TrkA inhibitor, significantly reduced the phosphorylation of ERK1/2 and AKT. Taken together, these results suggested that NGF activated ERK1/2 and AKT signaling after the recognizing the TrkA receptor ( Figure 3B ).
The ERK1/2 and AKT pathways were required for NGFinduced VEGF expression in Müller cells:
To detect whether ERK1/2 and PI3K/AKT signaling is involved in VEGF elevation by NGF, the Müller cells were treated with NGF in the presence or absence of the TrkA, ERK1/2, or PI3K/AKT inhibitors. After 12 or 24 h of stimulation, the supernatants were collected and detected with ELISA. As shown in Figure  4 , NGF increased the production of VEGF in Müller cells, which was more prominent at 12 h than at 24 h. However, the K252a (TrkA inhibitor), U0126 (ERK1/2 pathway inhibitor), or LY294002 (PI3K/AKT inhibitor) combined treatment markedly decreased the increased VEGF expression induced by NGF (Figure 4 ; n=6, *p<0.05, **p<0.01, ***p<0.001).
NGF improves Müller cell proliferation via ERK1/2 and AKT signaling:
The ERK1/2 signaling pathway was closely related to the proliferation and differentiation of the cells, and an AKT-regulated cell cycle has been widely reported. Thus, we evaluated the role of NGF in Müller cell proliferation and used signaling inhibitors to detect the underlying mechanism. We performed a morphological assay using trypan blue staining and live cell counting and found that NGF could promote cell proliferation and ERK1/2 or PI3K/AKT was involved. We further used the MTT assay according to previous studies. As shown in Figure 5 , we found NGF increased the proliferation of the Müller cells, which could be inhibited by ERK1/2 or PI3K/AKT inhibitors at different doses and time points, at 24, 48, and 72 h (n=6, *p<0.05, **p<0.01, ***p<0.001). 
DISCUSSION
In the retina, NGF supports the survival of retinal ganglion cells (RGCs) and photoreceptors against degeneration directly or induces other neurotrophic factor expression from Müller cells to indirectly promote photoreceptor survival [1, 3] . In this study, we showed that NGF significantly increases the secretion of VEGF from Müller cells in a time-dependent manner. This effect is mediated by TrkA recognition and then the activation of the ERK1/2 and PI3K/AKT signaling pathways. Furthermore, NGF promoted Müller cell proliferation via the ERK1/2 and PI3K/AKT pathways. These data suggested that NGF has the potential to induce VEGF generation and increase Müller proliferation, which may lead Figure 2 . NGF increased the expression of VEGF in Müller cells. Müller cells were treated with 100 ng/ml of nerve growth factor (NGF) compared with an equal amount of bovine serum albumin (BSA) control. After 12 or 24 h, vascular endothelial growth factor (VEGF) protein expression in the supernatants was significantly increased in the NGF-treated group according to the enzyme-linked immunosorbent assay (ELISA). Importantly, the VEGF increase after 24 h was significantly higher than that after the 12 h treatments. There was no statistically significant difference between 12 and 24 h in the BSA treatment group with a p value equal to 0.0644. n=6, *p<0.05, *** p<0.001. to gliosis, the critical pathological changes that occur in many retinal angiogenic and proliferative diseases.
NGF, the first discovered member of the neurotrophin family, has been extensively researched for its protective role in neurons. The expression of NGF and its high affinity receptor TrkA is increased compensatively in many pathological conditions to protect tissue function, such as ocular hypertension, neurogenic inflammation, oxygen-induced retinopathy, etc. [21, 39, 40] . However, limited research has shown the role of NGF in Müller glia cells. Gliosis plays an important role in neurodegeneration, diabetic retinopathy, retinal detachment as well as retinal injury, and even in the physiologic aging of the retina [25, 26, 41, 42] . In this study, we revealed that NGF promoted proliferation of Müller cells, indicating that an excess dose of NGF might induce gliosis, which might lead to secondary injury.
Müller cells, as an important bridge connecting nerves and blood vessels in the retina, are an important source of growth factors and cytokines. Among them, VEGF is the most potent proangiogenic factor and contributes to retinal neovascularization under different conditions. Many studies reported that VEGF is mostly derived from Müller cells in pathological conditions [11, 23, 43, 44] . As a pool of VEGF, Müller cells produce and secrete VEGF in response to many stimuli. Our previous study showed that retinal glia activation is involved in inflammation-induced angiogenesis in the retina and that an intravitreal NGF injection enhances retinal neovascularization [21, 45] . Our findings in this study extend that NGF has the potential to promote angiogenesis via VEGF elevation in Müller cells and the activation and proliferation of Müller cells. We found that NGF significantly increases VEGF expression in Müller cells. In addition, because NGF utilizes a receptor-coupling event, we also found that TrkA blockade, the receptor for NGF, abolished the VEGF increase, indicating that NGF induced VEGF expression via TrkA binding on Müller cells. Further research on the proangiogenic effect of NGF dependent on or independent of VEGF is warranted. In addition, increasing evidence suggests the importance of NGF-TrkA signaling in Müller cells. NGF/TrkA plays an important role in the neural retina under normal or pathological conditions. Garcia et al. showed that TrkA was widely distributed in Müller cells after retinal ischemia-reperfusion in vivo [46] . Q. Jian et al. found that cultured rat bone marrow mesenchymal stem cells (rBMSCs) secrete nerve growth factor in vitro and that rBMSCs transplantation induced TrkA expression, cell proliferation, and dedifferentiation of Müller cells in vivo [10] . Consistent with previous reports, our results showed that NGF promotes VEGF production and cellular proliferation of Müller cells in vitro, which indicates that NGF has the potential to be involved in the retinal pathological condition by targeting Müller cells.
In this study, NGF significantly upregulated VEGF expression in Müller cells in vitro, which is mediated by the binding of the TrkA receptor. Mechanistically, we found that NGF induced VEGF expression in Müller cells via PI3K/ AKT and ERK1/2 signaling, which are the canonical kinase cascades. NGF activated ERK1/2 and AKT signaling 5 min after stimulation; the VEGF increase occurred at 12 and 24 h, and was more obvious after the 24 h stimulation. A possible reason may be that protein synthesis takes some time due to the complicated and time-consuming processes, which include DNA transcription, mRNA translation, and post-translational modification protein trafficking and secretion. Several pathways are shown to be involved in the angiogenesis process induced by the angiogenic growth factors. The PI3K/AKT pathway is activated upon the binding of extracellular growth factors to their respective transmembrane receptor tyrosine kinases. It is an important signaling molecule that is associated with endothelial cell survival and migration [47] . Consistent with other research, we found that the PI3K/AKT pathway mediated the survival and proliferation of Müller cells as well as VEGF generation, which are all involved in angiogenesis. In addition, the ERK1/2 pathway is activated by VEGF and FGF has also been implicated in the regulation of endothelial cell motility and survival. In this study, an ERK1/2 inhibitor blocked the activation of ERK1/2 and suppressed VEGF secretion and Müller cell proliferation, indicating that ERK1/2 activation is also required in gliosis. Therefore, the western blot and MTT assay results revealed that the inhibitory effects of the TrkA and PI3K/AKT inhibitors seem to be quite potent, while both drugs have only moderate effects on blocking NGF-induced VEGF production. The suppressive role of the ERK1/2 inhibitor in NGF-induced VEGF production appeared more potent than that of the PI3K/AKT inhibitor, indicating that the ERK1/2 signaling pathway played a more important role in VEGF secretion than the AKT signaling pathway. Taken together, these data suggested that NGF exerted various roles dominantly mediated by different signaling pathways. In addition, a TrkA inhibitor also suppressed the phosphorylation of AKT and ERK1/2 signaling, confirming that the TrkA receptor is involved in signal transduction to AKT and ERK1/2 signaling.
In summary, we showed that Müller cells express the high-affinity NGF receptor TrkA. The NGF/TrkA interaction induced VEGF secretion via the PI3K/AKT and ERK1/2 signaling pathway in Müller cells. In addition, NGF promoted the proliferation of Müller cells that was also mediated by PI3K/AKT and ERK1/2 signaling, indicating the potent gliosis role of NGF. Thus, NGF has a potential role in Müller cell-induced angiogenesis and gliosis, in addition to its role in neuroprotection, providing directions for future research on neural-vascular coupling and communication in the retina.
APPENDIX 1. IDENTIFICATION OF THE CULTURED RETINAL MÜLLER CELLS.
The cultured retinal Müller cells were identified by immunocytochemistry using antibodies against the Müller cell markers GS and vimentin, which is a cytoskeletal intermediate filament protein in Müller cells. The nuclei were stained with DAPI. Almost all cells were positive for GS and vimentin (A). The negative controls are shown in B. To access the data, click or select the words "Appendix 1."
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